An animal model of B-cell lymphoma suggests that the key to the establishment of anti-TME is CD4+ T cells and that CD4+ T cells are able to predict patient prognosis (Ding et al., 2012). This evidence concerns the gene CD4 and B-cell non-Hodgkin lymphoma.